<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132801">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01891578</url>
  </required_header>
  <id_info>
    <org_study_id>ONC/OSS-04/2010</org_study_id>
    <nct_id>NCT01891578</nct_id>
  </id_info>
  <brief_title>Evaluation of Immunological Reconstitution After Haploidentical Bone Marrow Transplantation</brief_title>
  <official_title>Evaluation of Immunological Reconstitution After Haploidentical Bone Marrow Transplantation Using a Nonmyeloablative Preparative Regimen and Post-transplant Cyclophosphamide, in Patients With Poor Prognosis Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Armando Santoro, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <authority>Italy: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of immunological reconstitution after haploidentical BMT using a nonmyeloablative
      preparative regimen and post-transplant cyclophosphamide in patients with poor prognosis
      lymphoma
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Evaluation of  T lymphocytes and NK cells absolute number</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of discrete T-cells populations</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation, by flow cytometry, of discrete T cell populations, including CD4+ and CD8+ TN, TSCM, TCM and TEM, NK and NKT cells, B cells, dendritic cell subsets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of antigen-specific T cell populations</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation of antigen-specific T cell frequency towards CMV, EBV and influenza virus by MHC tetramers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of antigen-specific T lymphocyte's functionality</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>antigen-specific T lymphocyte's functionality towards tumor cell line evaluated using a degranulation assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of cytokines production by IL-2 and anti-CD16 activated NK cells</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">23</enrollment>
  <condition>Lymphoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with lymphoma (any histology)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with lymphoma (any histology) relapsed after high dose chemotherapy and in
             partial remission, complete remission or stable disease after the last CT line that

          -  Signed informed consent to perform an haploidentical allo-BMT using a
             nonmyeloablative preparative regimen and post-transplant cyclophosphamide

        Exclusion Criteria:

        none
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armando Santoro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 28, 2013</lastchanged_date>
  <firstreceived_date>May 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Clinico Humanitas</investigator_affiliation>
    <investigator_full_name>Armando Santoro, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
